SG10202002181UA - Imidazolonyl quinolines and use thereof as atm kinase inhibitors - Google Patents
Imidazolonyl quinolines and use thereof as atm kinase inhibitorsInfo
- Publication number
- SG10202002181UA SG10202002181UA SG10202002181UA SG10202002181UA SG10202002181UA SG 10202002181U A SG10202002181U A SG 10202002181UA SG 10202002181U A SG10202002181U A SG 10202002181UA SG 10202002181U A SG10202002181U A SG 10202002181UA SG 10202002181U A SG10202002181U A SG 10202002181UA
- Authority
- SG
- Singapore
- Prior art keywords
- imidazolonyl
- quinolines
- kinase inhibitors
- atm kinase
- atm
- Prior art date
Links
- BAHVJMJZUDCTPT-UHFFFAOYSA-N 4-quinolin-2-ylimidazol-2-one Chemical class O=C1N=CC(C=2N=C3C=CC=CC3=CC=2)=N1 BAHVJMJZUDCTPT-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15000968 | 2015-04-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202002181UA true SG10202002181UA (en) | 2020-05-28 |
Family
ID=52814780
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201708065QA SG11201708065QA (en) | 2015-04-02 | 2016-03-31 | Imidazolonyl quinolines and use thereof as atm kinase inhibitors |
SG10202002181UA SG10202002181UA (en) | 2015-04-02 | 2016-03-31 | Imidazolonyl quinolines and use thereof as atm kinase inhibitors |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201708065QA SG11201708065QA (en) | 2015-04-02 | 2016-03-31 | Imidazolonyl quinolines and use thereof as atm kinase inhibitors |
Country Status (24)
Country | Link |
---|---|
US (5) | US10457677B2 (es) |
EP (3) | EP3277681B1 (es) |
JP (2) | JP6791873B2 (es) |
KR (2) | KR20240044525A (es) |
CN (3) | CN107889488B (es) |
AU (3) | AU2016239270B2 (es) |
BR (1) | BR122019005502B1 (es) |
CA (1) | CA2981365A1 (es) |
DK (2) | DK3277681T3 (es) |
ES (3) | ES2946507T3 (es) |
HR (2) | HRP20191396T1 (es) |
HU (2) | HUE045477T2 (es) |
IL (3) | IL254714B (es) |
LT (2) | LT3560924T (es) |
MX (2) | MX2017012613A (es) |
PL (2) | PL3560924T3 (es) |
PT (2) | PT3277681T (es) |
RS (2) | RS59139B1 (es) |
RU (1) | RU2743343C2 (es) |
SG (2) | SG11201708065QA (es) |
SI (2) | SI3277681T1 (es) |
TR (1) | TR201911244T4 (es) |
WO (1) | WO2016155884A1 (es) |
ZA (1) | ZA201707423B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS59139B1 (sr) * | 2015-04-02 | 2019-09-30 | Merck Patent Gmbh | Imidazolonilhinolini i njihova primena kao inhibitora atm kinaze |
GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
GB201519406D0 (en) * | 2015-11-03 | 2015-12-16 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
US11547703B2 (en) | 2017-02-27 | 2023-01-10 | Impact Therapeutics (Shanghai), Inc | Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof |
JOP20190209A1 (ar) * | 2017-03-16 | 2019-09-12 | Astrazeneca Ab | مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان |
CN111587126A (zh) | 2018-01-12 | 2020-08-25 | 普罗林科斯有限责任公司 | 组合剂型和用于验证的造影剂毒性最小化方案 |
KR20200131270A (ko) * | 2018-03-14 | 2020-11-23 | 메르크 파텐트 게엠베하 | 대상체에서의 암을 치료하기 위한 화합물 및 이의 용도 |
ES2965494T3 (es) | 2018-04-12 | 2024-04-15 | Bayer Ag | Derivados de N-(ciclopropilmetil)-5-(metilsulfonil)-n-{1-[1-(pirimidin-2-il)-1H-1,2,4-triazol-5-il]etil}benzamida y los correspondientes derivados de piridina-carboxamida como plaguicidas |
CN110386932A (zh) * | 2018-04-20 | 2019-10-29 | 艾科思莱德制药公司 | 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 |
WO2019201283A1 (en) * | 2018-04-20 | 2019-10-24 | Xrad Therapeutics, Inc. | Dual atm and dna-pk inhibitors for use in anti-tumor therapy |
GB201814487D0 (en) * | 2018-09-06 | 2018-10-24 | Cycle Pharmaceuticals Ltd | Cancer |
CN109045042A (zh) * | 2018-09-21 | 2018-12-21 | 上海交通大学医学院附属上海儿童医学中心 | Atm抑制剂在制备抑制急性淋巴细胞性白血病复发的药物中的应用 |
MX2021003739A (es) * | 2018-09-30 | 2022-04-07 | Medshine Discovery Inc | Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos. |
SG11202110480YA (en) * | 2019-03-27 | 2021-10-28 | Merck Patent Gmbh | Imidazolonylquinoline compounds and therapeutic uses thereof |
AU2020322026A1 (en) * | 2019-07-30 | 2022-02-03 | Xrad Therapeutics, Inc. | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy |
KR20220095205A (ko) | 2019-11-01 | 2022-07-06 | 아레스 트레이딩 에스.아. | 암의 치료를 위한 방사선요법과 PD-1, TGFβ 및 ATM의 조합 억제 |
US11685734B2 (en) | 2019-12-04 | 2023-06-27 | Chdi Foundation, Inc. | ATM kinase inhibitors and compositions and methods of use thereof |
WO2021139814A1 (zh) * | 2020-01-09 | 2021-07-15 | 南京明德新药研发有限公司 | 喹啉并咪唑类化合物及其应用 |
CN115380031A (zh) * | 2020-03-30 | 2022-11-22 | 南京明德新药研发有限公司 | 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用 |
EP4168010A1 (en) * | 2020-06-18 | 2023-04-26 | Merck Patent GmbH | Compounds for the treatment of viral infections |
JP2023539715A (ja) | 2020-06-24 | 2023-09-19 | アストラゼネカ ユーケー リミテッド | 抗体-薬物コンジュゲートとatm阻害剤との組合わせ |
WO2022058351A1 (en) | 2020-09-18 | 2022-03-24 | Merck Patent Gmbh | Pharmaceutical preparation |
AU2020468487B2 (en) | 2020-09-21 | 2024-02-29 | Wei Zhong | Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo(4,5-c) quinolin-2-one compounds with blood-brain barrier penetrable capability |
EP3992191A1 (en) | 2020-11-03 | 2022-05-04 | Deutsches Krebsforschungszentrum | Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors |
CN115232122B (zh) * | 2021-04-23 | 2024-05-31 | 石药集团中奇制药技术(石家庄)有限公司 | 炔类化合物及其制备和应用 |
CN115716829B (zh) * | 2022-11-13 | 2024-05-31 | 药康众拓(江苏)医药科技有限公司 | 一种喹啉并咪唑酮联氘代吡唑类化合物及其应用 |
WO2024112796A1 (en) * | 2022-11-23 | 2024-05-30 | Forward Therapeutics, Inc. | MODULATORS OF TNF-α ACTIVITY |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
ATE234299T1 (de) * | 1999-12-03 | 2003-03-15 | Pfizer Prod Inc | Sulfamoylheteroarylpyrazolverbindungen zur verwendung als analgetisches/entzündungshemmendes mittel |
GB0211649D0 (en) | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
EP1879893B1 (en) | 2005-03-21 | 2010-06-02 | Ferrer Internacional, S.A. | Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
BRPI0617987A2 (pt) * | 2005-10-06 | 2011-08-16 | Auspex Pharmaceuticals Inc | composição, composição farmacêutica, forma de dosagem efervescente, composição farmacêutica oral de comprimidos unitários múltiplos, forma de dosagem farmacêutica de liberação prolongada, forma de dosagem farmacêutica revestida entérica, forma de dosagem farmacêutica estável para administração oral a sujeitos mamìferos, método para tratamento de doenças relacionadas a ácido gástrico pela inibição de secreção de ácido gástrico, método para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori, processo para preparar um composto da fórmula 3, processo para preparar um composto da fórmula 5, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relacionadas a ácido gástrico, pela inibição de secreção de ácido gástrico, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relecionadas a ácido gástrico pela inibição de secreção de ácido gástrico |
US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
CN101616672A (zh) | 2007-02-20 | 2009-12-30 | 诺瓦提斯公司 | 作为脂质激酶和mTOR双重抑制剂的咪唑并喹啉类 |
MX2010010505A (es) | 2008-03-26 | 2010-10-26 | Novartis Ag | Imidazoquinolinas y derivados de pirimidina como moduladores potentes de los procesos angiogenicos impulsados por el factor de crecimiento endotelial vascular (vegf). |
CN102118968A (zh) | 2008-06-10 | 2011-07-06 | 雅培制药有限公司 | 新的三环化合物 |
AU2009299927B2 (en) | 2008-10-01 | 2013-05-30 | Novartis Ag | Smoothened antagonism for the treatment of hedgehog pathway-related disorders |
EP2438064A1 (en) | 2009-06-04 | 2012-04-11 | Novartis AG | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES |
EP2438063A1 (en) | 2009-06-04 | 2012-04-11 | Novartis AG | 1h-imidazo[4,5-c]quinolinone compounds, useful for the treatment of proliferative diseases |
GB0919423D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
KR20130017086A (ko) * | 2010-03-16 | 2013-02-19 | 메르크 파텐트 게엠베하 | 모르폴리닐퀴나졸린 |
CA2803665C (en) * | 2010-06-28 | 2019-03-05 | Dieter Dorsch | 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer |
CN102372711B (zh) | 2010-08-18 | 2014-09-17 | 山东轩竹医药科技有限公司 | 咪唑并喹啉类PI3K和mTOR双重抑制剂 |
DE102010035744A1 (de) | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
CN102399218A (zh) | 2010-09-16 | 2012-04-04 | 和记黄埔医药(上海)有限公司 | 一类并合三杂环及其作为pi3k抑制剂的用途 |
AU2011336478A1 (en) | 2010-12-03 | 2013-06-06 | Novartis Ag | Pharmaceutical compositions |
CN103012398B (zh) | 2011-09-19 | 2015-10-14 | 上海恒瑞医药有限公司 | 咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用 |
US9879003B2 (en) | 2012-04-11 | 2018-01-30 | Dana-Farber Cancer Institute, Inc. | Host targeted inhibitors of dengue virus and other viruses |
CN104349771A (zh) | 2012-06-06 | 2015-02-11 | 诺华股份有限公司 | 用于治疗肿瘤疾病的17α-羟化酶(C17,20-裂解酶)抑制剂和特定PI-3K抑制剂的组合 |
NO2714752T3 (es) * | 2014-05-08 | 2018-04-21 | ||
RS59139B1 (sr) * | 2015-04-02 | 2019-09-30 | Merck Patent Gmbh | Imidazolonilhinolini i njihova primena kao inhibitora atm kinaze |
-
2016
- 2016-03-31 RS RS20190993A patent/RS59139B1/sr unknown
- 2016-03-31 SI SI201630345T patent/SI3277681T1/sl unknown
- 2016-03-31 CN CN201680031887.8A patent/CN107889488B/zh active Active
- 2016-03-31 PT PT16717560T patent/PT3277681T/pt unknown
- 2016-03-31 HU HUE16717560A patent/HUE045477T2/hu unknown
- 2016-03-31 WO PCT/EP2016/000542 patent/WO2016155884A1/de active Application Filing
- 2016-03-31 KR KR1020247009513A patent/KR20240044525A/ko active Search and Examination
- 2016-03-31 ES ES21165573T patent/ES2946507T3/es active Active
- 2016-03-31 CN CN202010644109.4A patent/CN111747952A/zh active Pending
- 2016-03-31 LT LTEP19172903.7T patent/LT3560924T/lt unknown
- 2016-03-31 MX MX2017012613A patent/MX2017012613A/es active IP Right Grant
- 2016-03-31 US US15/563,680 patent/US10457677B2/en active Active
- 2016-03-31 BR BR122019005502-5A patent/BR122019005502B1/pt active IP Right Grant
- 2016-03-31 CA CA2981365A patent/CA2981365A1/en active Pending
- 2016-03-31 AU AU2016239270A patent/AU2016239270B2/en active Active
- 2016-03-31 RS RS20210817A patent/RS62082B1/sr unknown
- 2016-03-31 PL PL19172903T patent/PL3560924T3/pl unknown
- 2016-03-31 HU HUE19172903A patent/HUE054745T2/hu unknown
- 2016-03-31 LT LTEP16717560.3T patent/LT3277681T/lt unknown
- 2016-03-31 EP EP16717560.3A patent/EP3277681B1/de active Active
- 2016-03-31 MX MX2020011558A patent/MX2020011558A/es unknown
- 2016-03-31 EP EP21165573.3A patent/EP3868761B1/de active Active
- 2016-03-31 CN CN202010644289.6A patent/CN111689963A/zh active Pending
- 2016-03-31 ES ES16717560T patent/ES2741853T3/es active Active
- 2016-03-31 PL PL16717560T patent/PL3277681T3/pl unknown
- 2016-03-31 KR KR1020177031770A patent/KR102652052B1/ko active IP Right Grant
- 2016-03-31 PT PT191729037T patent/PT3560924T/pt unknown
- 2016-03-31 TR TR2019/11244T patent/TR201911244T4/tr unknown
- 2016-03-31 JP JP2017551589A patent/JP6791873B2/ja active Active
- 2016-03-31 DK DK16717560.3T patent/DK3277681T3/da active
- 2016-03-31 DK DK19172903.7T patent/DK3560924T3/da active
- 2016-03-31 SG SG11201708065QA patent/SG11201708065QA/en unknown
- 2016-03-31 SI SI201631240T patent/SI3560924T1/sl unknown
- 2016-03-31 ES ES19172903T patent/ES2880626T3/es active Active
- 2016-03-31 RU RU2017138100A patent/RU2743343C2/ru active
- 2016-03-31 SG SG10202002181UA patent/SG10202002181UA/en unknown
- 2016-03-31 EP EP19172903.7A patent/EP3560924B1/de active Active
-
2017
- 2017-09-26 IL IL254714A patent/IL254714B/en active IP Right Grant
- 2017-11-01 ZA ZA2017/07423A patent/ZA201707423B/en unknown
-
2019
- 2019-03-14 US US16/353,559 patent/US10745399B2/en active Active
- 2019-08-01 HR HRP20191396 patent/HRP20191396T1/hr unknown
- 2019-12-17 IL IL271494A patent/IL271494B/en active IP Right Grant
-
2020
- 2020-06-24 US US16/910,438 patent/US10975075B2/en active Active
- 2020-06-25 AU AU2020204241A patent/AU2020204241B2/en active Active
- 2020-11-05 JP JP2020185129A patent/JP7111790B2/ja active Active
-
2021
- 2021-03-17 US US17/204,619 patent/US11608338B2/en active Active
- 2021-04-22 IL IL282584A patent/IL282584B/en unknown
- 2021-06-23 HR HRP20210981TT patent/HRP20210981T1/hr unknown
-
2022
- 2022-10-21 AU AU2022256215A patent/AU2022256215A1/en active Pending
-
2023
- 2023-03-01 US US18/116,094 patent/US20230203034A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201707423B (en) | Imidazolonyl quinolines and use thereof as atm kinase inhibitors | |
IL279258B (en) | tyrosine kinase inhibitors | |
IL277239B (en) | mdm2 inhibitors and combinations thereof | |
PL3380479T3 (pl) | Triazolowe inhibitory acc i ich zastosowania | |
EP3171874A4 (en) | Imidazolyl kinase inhibitors and uses thereof | |
PL3380480T3 (pl) | Pirazolowe inhibitory acc i ich zastosowania | |
GB201605126D0 (en) | Inhibitors and their uses | |
IL259150B (en) | Pyrimidine derivative and use thereof | |
SG10201913927VA (en) | Kinase inhibitors and uses thereof | |
IL262400A (en) | Erbb inhibitors and uses thereof | |
HK1250926A1 (zh) | 抑制劑及其應用 | |
IL258690A (en) | Pyridone derivatives and their use as kinase inhibitors | |
GB201609580D0 (en) | Novel compounds and their use as kinase inhibitors | |
GB201519381D0 (en) | Kinase inhibitors | |
GB201519382D0 (en) | Kinase inhibitors | |
GB201509381D0 (en) | Novel compounds and their use as kinase inhibitors | |
GB201505460D0 (en) | Novel compounds and their use as kinase inhibitors | |
GB201505975D0 (en) | Inhibitors and their uses | |
GB201505971D0 (en) | Inhibitors and their uses |